Amgen (AMGN) Non-Current Debt (2009 - 2026)
Amgen (AMGN) posted quarterly Non-Current Debt of $51.9 billion for Q1 2026, down 3.94% year-over-year from $54.0 billion in Q1 2025, and up 3.76% quarter-over-quarter from $50.0 billion in Q4 2025.
Amgen (AMGN) Non-Current Debt (2009 - 2026) Analysis & Trends
Amgen's Non-Current Debt history runs 18 years deep, the most recent figure standing at $51.9 billion for Q1 2026.
- In Q1 2026, Non-Current Debt fell 3.94% year-over-year to $51.9 billion; the TTM figure through Mar 2026 stood at $51.9 billion (down 3.94% YoY), while the FY2025 annual figure was $50.0 billion, down 11.57% from the prior year.
- Non-Current Debt for Q1 2026 stood at $51.9 billion, up from $50.0 billion in the prior quarter.
- The five-year high for Non-Current Debt was $64.0 billion in Q1 2024, with the low at $36.5 billion in Q2 2022.
- The 5-year median for Non-Current Debt is $56.2 billion (2025), against an average of $53.1 billion.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt soared 69.11% in 2023, then fell 15.6% in 2025.
- Amgen's Non-Current Debt stood at $37.4 billion in 2022, then jumped by 69.11% to $63.2 billion in 2023, then decreased by 10.48% to $56.5 billion in 2024, then dropped by 11.57% to $50.0 billion in 2025, then gained by 3.76% to $51.9 billion in 2026.
- Business Quant data shows AMGN's Non-Current Debt at $51.9 billion in Q1 2026, $50.0 billion in Q4 2025, and $54.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.03 Bn | 634.27 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 470.29 Bn | 463.72 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 380.80 Bn | 373.66 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 302.80 Bn | 295.11 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 258.24 Bn | 253.34 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 237.40 Bn | 223.41 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 183.07 Bn | 179.89 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 161.54 Bn | 149.84 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 106.01 Bn | 101.85 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 55.05 Bn | 47.67 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.30 Bn |
| Mar 31, 2026 | 51.89 Bn |
| Dec 31, 2025 | 50.01 Bn |
| Sep 30, 2025 | 54.59 Bn |
| Jun 30, 2025 | 56.20 Bn |
| Mar 31, 2025 | 54.01 Bn |
| Dec 31, 2024 | 56.55 Bn |
| Sep 30, 2024 | 60.40 Bn |
| Jun 30, 2024 | 62.60 Bn |
| Mar 31, 2024 | 64.00 Bn |
| Dec 31, 2023 | 63.17 Bn |
| Sep 30, 2023 | 60.50 Bn |
| Jun 30, 2023 | 59.38 Bn |
| Mar 31, 2023 | 60.76 Bn |
| Dec 31, 2022 | 37.35 Bn |
| Sep 30, 2022 | 38.70 Bn |
| Jun 30, 2022 | 36.50 Bn |
| Mar 31, 2022 | 36.90 Bn |
| Dec 31, 2021 | 33.30 Bn |
| Sep 30, 2021 | 37.60 Bn |